Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Income towards Parent Company (2018 - 2025)

Historic Income towards Parent Company for Inmune Bio (INMB) over the last 7 years, with Q3 2025 value amounting to -$7.4 million.

  • Inmune Bio's Income towards Parent Company rose 3950.02% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.4 million, marking a year-over-year decrease of 2365.75%. This contributed to the annual value of -$42.6 million for FY2024, which is 4207.88% down from last year.
  • As of Q3 2025, Inmune Bio's Income towards Parent Company stood at -$7.4 million, which was up 3950.02% from -$24.6 million recorded in Q2 2025.
  • Over the past 5 years, Inmune Bio's Income towards Parent Company peaked at -$4.5 million during Q1 2021, and registered a low of -$24.6 million during Q2 2025.
  • For the 5-year period, Inmune Bio's Income towards Parent Company averaged around -$8.9 million, with its median value being -$8.4 million (2023).
  • Data for Inmune Bio's Income towards Parent Company shows a peak YoY increase of 3950.02% (in 2025) and a maximum YoY decrease of 14907.25% (in 2025) over the last 5 years.
  • Over the past 5 years, Inmune Bio's Income towards Parent Company (Quarter) stood at -$9.0 million in 2021, then soared by 37.52% to -$5.6 million in 2022, then tumbled by 48.51% to -$8.4 million in 2023, then fell by 12.98% to -$9.5 million in 2024, then grew by 21.49% to -$7.4 million in 2025.
  • Its Income towards Parent Company was -$7.4 million in Q3 2025, compared to -$24.6 million in Q2 2025 and -$9.9 million in Q1 2025.